Scheduled versus Pro Re Nata Dosing in the VIEW Trials
Gisbert Richard, Jordi Mones, Sebastian Wolf, Jean Francois Korobelnik, Robyn Guymer, Michaella Goldstein, Christiane Norenberg, Rupert Sandbrink, Oliver Zeitz
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2015
PURPOSE: To analyze visual acuity (VA) outcomes before and after preplanned treatment regimen change in the VIEW studies at week 52 (W52). DESIGN: Multiple post hoc analyses for retrospectively defined subgroups in 2 multicenter, multinational, double-masked trials. PARTICIPANTS: Two thousand four hundred fifty-seven neovascular age-related macular degeneration (AMD) patients. METHODS: Patients were randomized to treatment with 0.5 mg ranibizumab given monthly, a 0.5-mg or 2-mg intravitreal aflibercept injection given monthly, or 2 mg intravitreal aflibercept given every other month, after 3 initial monthly doses, up to W52. From W52 through W96, patients received their original dosing assig..View full abstract
The author(s) have made the following disclosure(s): G.R.: Financial support - Bayer HealthCare (Berlin, Germany), Pfizer (Cambridge, MA), Carl Zeiss Meditec (Jena, Germany), Novartis AG (Basel, Switzerland), Pixium Vision (Paris, France); Consultant - Carl Zeiss Meditec (Jena, Germany), Pixium Vision (Paris, France).